Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability and Tolerability of BIBV 308 SE Extended Release Capsules
NCT02223013Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 1999
- Primary completion
- May 1999
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of terbogrel (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve at steady state at 84 hours, Maximum plasma concentration at steady state at 84 hours and 1 more. Started Apr 1999; status: completed.
02
Drugs
terbogrel
Beyond the preview
Go deeper on NCT02223013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223013.